Company Updates

LifeVantage CEO Steve Fife to retire in April 2026

LFVN

LifeVantage (Nasdaq: LFVN) said on February 4, 2026 that chief executive Steve Fife will retire in April 2026. The board is searching for a successor and has not named one.

Investor Chat

Scorecard

LFVN
Investor Impact: 4.5/10, ModerateHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
ModerateHigh evidence
Investment Attractiveness: 5/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

By the aibio.space news desk

A surgeon in a mask and cap
A surgeon in a mask and cap. Photo: U.S. Navy Medicine, CC0, via rawpixel. The picture shows the field, not the companies named.

LifeVantage Corporation (Nasdaq: LFVN) said on February 4, 2026 that Steven R. Fife, its president and chief executive officer, will retire in April 2026. Fife notified the board of the decision on January 30, 2026, according to a Form 8-K filed February 4, 2026. The company said the board is conducting an extensive executive search.

Why is this important: The company had not named a successor when it made the announcement. Cash and cash equivalents fell from $20,201 thousand at June 30, 2025 to $13,091 thousand at September 30, 2025, according to the company's 10-Q. Shareholders are left waiting for a name while the cash balance has fallen.

Raymond Greer, the chairman of the board, said in the company's release that the board had carried out succession planning for Fife's eventual retirement. In our view, an orderly retirement is preferable to a sudden exit, but the company has given shareholders a date and no name. The board should explain its search before Fife leaves in April, not after.

What the 8-K and the release say about the transition

The company filed the news under Item 5.02, which covers departures and appointments of certain officers. The filing says Fife's decision is not the result of any disagreement with the company on its operations, financial policies or practices. It does not name an interim chief executive.

Fife will continue as president and chief executive officer during the transition period, according to the release. The release also describes him as a member of the board of directors, so his retirement removes a board seat as well as the chief executive role. He has served nine years at LifeVantage.

The board said it expects to name a new chief executive in the coming months, and the release calls the board's process an extensive executive search. Greer said in the release: "Steve has been an exceptional leader", and he credited Fife with the company's growth across multiple dimensions.

What the same filing also reports

The 8-K was signed by Carl A. Aure, the chief financial officer. It furnishes two releases. Exhibit 99.1 reports financial results for the three and six months ended December 31, 2025, and Exhibit 99.2 announces Fife's retirement. The filing says the results are furnished under Item 2.02 and are not deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934.

That pairing matters for readers. The chief executive's exit was disclosed on the same day as a quarterly report, so the board's search and the next results will be read together by shareholders.

LifeVantage calls itself the Activation company and describes itself as a pioneer in nutrigenomics. The release defines that field as the study of how nutrition and naturally occurring compounds can unlock a person's genes. Its product line includes Protandim.

The Form 10-Q for the quarter ended September 30, 2025 reports net revenue of $47,561 thousand for the quarter, against $47,214 thousand a year earlier. The same filing shows cash and cash equivalents of $13,091 thousand at September 30, 2025, against $20,201 thousand at June 30, 2025.

The filings cited here name no clinical trial and no ClinicalTrials.gov number for Protandim or the company's other products. Product claims in the filings are the company's own statements about its supplements, and this story does not treat them as clinical findings.

What comes next for the chief executive role

The next dated event the company has named is Fife's retirement in April 2026. The release does not name a date for the successor announcement, and it does not say whether the board has chosen a candidate or whether an interim chief executive will serve before Fife leaves. The 8-K gives no compensation terms for the new role.

Shareholders should watch whether the board names a chief executive before Fife leaves. They should also watch whether revenue and cash trends change in the company's next filings.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.